Laser treatment at birth may prevent vision loss from Norrie's disease

Article

Pre-term genetic diagnosis with immediate laser treatment after birth could help prevent vision loss in people affected by Norrie?s disease.

Pre-term genetic diagnosis with immediate laser treatment after birth could help prevent vision loss in people affected by Norrie's disease, according to data published in Ophthalmology.

Dr Michael J. Shapiro et al., from the Illinois Eye and Ear Infirmary, University of Illinois, and Retina Consultants, Illinois, Chicago, USA, were the first to report a case of prophylactic laser treatment to prevent blindness in a patient who was diagnosed with Norrie's disease through genetic testing with amniocentesis.

The physicians examined a 37-week gestational age male who had a family history of Norrie’s disease and had undergone prenatal amniocentesis foetal-genetic testing at 23 weeks gestation. A C520T (nonsense) mutation was found in the Norrie’s disease gene, which was confirmed by examination under anaethesia on the first day of life. Laser photocoagulation was applied to the avascular retina bilaterally and the patient was followed closely.

There was complete regression of extraretinal fibrovascular proliferation observed one month after the laser treatment and no retinal detachment had occurred at 24 months. The Teller visual acuity of the patient was 20/100 at 23 months in both eyes and the patient’s vision and developmental milestones were determined to be appropriate for his age range.

As a result of these findings it was reported that performing pre-term genetic diagnosis and following with immediate laser treatment at birth could preserve vision in patients affected with Norrie’s disease.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.